Inhibition of LRRK2 kinase activity stimulates macroautophagy

[1]  A. Mamais,et al.  Phosphorylation of 4E-BP1 in the Mammalian Brain Is Not Altered by LRRK2 Expression or Pathogenic Mutations , 2012, PloS one.

[2]  C. Manzoni.  LRRK2 and autophagy: a common pathway for disease. , 2012, Biochemical Society transactions.

[3]  E. Greggio.  Role of LRRK2 kinase activity in the pathogenesis of Parkinson's disease. , 2012, Biochemical Society transactions.

[4]  N. Gray,et al.  GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. , 2012, Bioorganic & medicinal chemistry letters.

[5]  C. Thompson,et al.  Therapeutic targets in cancer cell metabolism and autophagy , 2012, Nature Biotechnology.

[6]  M. Memo,et al.  Disease-specific phenotypes in dopamine neurons from human iPS-based models of genetic and sporadic Parkinson's disease , 2012, EMBO molecular medicine.

[7]  Eun-Young Kim,et al.  Impaired Inflammatory Responses in Murine Lrrk2-Knockdown Brain Microglia , 2012, PloS one.

[8]  D. Jewell,et al.  Functional consequences of mutations in the autophagy genes in the pathogenesis of Crohn's disease , 2012, Inflammatory bowel diseases.

[9]  M. Cookson,et al.  Parkinson disease, cancer, and LRRK2 , 2012, Neurology.

[10]  M. Cookson,et al.  Is inhibition of kinase activity the only therapeutic strategy for LRRK2-associated Parkinson's disease? , 2012, BMC Medicine.

[11]  D. Standaert,et al.  LRRK2 Inhibition Attenuates Microglial Inflammatory Responses , 2012, The Journal of Neuroscience.

[12]  C. Manzoni,et al.  LRRK2 and Human Disease: A Complicated Question or a Question of Complexes? , 2012, Science Signaling.

[13]  H. Cai,et al.  Loss of leucine-rich repeat kinase 2 causes age-dependent bi-phasic alterations of the autophagy pathway , 2012, Molecular Neurodegeneration.

[14]  S. Bruley des Varannes,et al.  Parkinson disease , 2011, Neurology.

[15]  G. Drewes,et al.  Chemoproteomics-based design of potent LRRK2-selective lead compounds that attenuate Parkinson's disease-related toxicity in human neurons. , 2011, ACS chemical biology.

[16]  G. Churchill,et al.  Leucine-rich repeat kinase 2 regulates autophagy through a calcium-dependent pathway involving NAADP , 2011, Human molecular genetics.

[17]  J. Ioannidis,et al.  Association of LRRK2 exonic variants with susceptibility to Parkinson's disease: a case–control study , 2011, The Lancet Neurology.

[18]  A. West,et al.  Autophosphorylation in the leucine-rich repeat kinase 2 (LRRK2) GTPase domain modifies kinase and GTP-binding activities. , 2011, Journal of molecular biology.

[19]  M. Cookson,et al.  LRRK2 Kinase Activity Is Dependent on LRRK2 GTP Binding Capacity but Independent of LRRK2 GTP Binding , 2011, PloS one.

[20]  Carolinne de Sales Marques,et al.  Leprosy susceptibility: genetic variations regulate innate and adaptive immunity, and disease outcome. , 2011, Future microbiology.

[21]  David S. Park,et al.  Parkinson’s disease-linked LRRK2 is expressed in circulating and tissue immune cells and upregulated following recognition of microbial structures , 2011, Journal of Neural Transmission.

[22]  Y. Liu,et al.  Dopaminergic Neuronal Loss, Reduced Neurite Complexity and Autophagic Abnormalities in Transgenic Mice Expressing G2019S Mutant LRRK2 , 2011, PloS one.

[23]  D. Rubinsztein,et al.  Protein misfolding disorders and macroautophagy , 2011, Current opinion in cell biology.

[24]  N. Gray,et al.  Characterization of a selective inhibitor of the Parkinson’s disease kinase LRRK2 , 2011, Nature chemical biology.

[25]  Mohamad Saad,et al.  Imputation of sequence variants for identification of genetic risks for Parkinson's disease: a meta-analysis of genome-wide association studies , 2011, The Lancet.

[26]  N. Mizushima,et al.  p62 targeting to the autophagosome formation site requires self-oligomerization but not LC3 binding , 2011, The Journal of cell biology.

[27]  V. Baekelandt,et al.  Insight into the mode of action of the LRRK2 Y1699C pathogenic mutant , 2011, Journal of neurochemistry.

[28]  Mark R. Cookson,et al.  The role of leucine-rich repeat kinase 2 (LRRK2) in Parkinson's disease , 2010, Nature Reviews Neuroscience.

[29]  Mark J Daly,et al.  LRRK2 Is Involved in the IFN-γ Response and Host Response to Pathogens , 2010, The Journal of Immunology.

[30]  D. Rigden,et al.  Mammalian Atg18 (WIPI2) localizes to omegasome-anchored phagophores and positively regulates LC3 lipidation , 2010, Autophagy.

[31]  R. J. Kelleher,et al.  Loss of leucine-rich repeat kinase 2 causes impairment of protein degradation pathways, accumulation of α-synuclein, and apoptotic cell death in aged mice , 2010, Proceedings of the National Academy of Sciences.

[32]  A. Gitler,et al.  GTPase Activity Plays a Key Role in the Pathobiology of LRRK2 , 2010, PLoS genetics.

[33]  M. Cookson,et al.  The Parkinson's Disease Associated LRRK2 Exhibits Weaker In Vitro Phosphorylation of 4E-BP Compared to Autophosphorylation , 2010, PloS one.

[34]  D. Klionsky,et al.  Regulation mechanisms and signaling pathways of autophagy. , 2009, Annual review of genetics.

[35]  Richard Wade-Martins,et al.  LRRK2 regulates autophagic activity and localizes to specific membrane microdomains in a novel human genomic reporter cellular model. , 2009, Human molecular genetics.

[36]  A. Wittinghofer,et al.  It takes two to tango: regulation of G proteins by dimerization , 2009, Nature Reviews Molecular Cell Biology.

[37]  P. Lewis.  The function of ROCO proteins in health and disease , 2009, Biology of the cell.

[38]  M. Cookson,et al.  Leucine-rich repeat kinase 2 mutations and Parkinson’s disease: three questions , 2009, ASN neuro.

[39]  M. Duchen,et al.  CLIC1 Function Is Required for β-Amyloid-Induced Generation of Reactive Oxygen Species by Microglia , 2008, The Journal of Neuroscience.

[40]  R. Takahashi,et al.  Phosphorylation of 4E‐BP by LRRK2 affects the maintenance of dopaminergic neurons in Drosophila , 2008, The EMBO journal.

[41]  Daniel J Klionsky,et al.  The Atg8 and Atg12 ubiquitin‐like conjugation systems in macroautophagy , 2008, EMBO reports.

[42]  Judy H. Cho,et al.  Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease , 2008, Nature Genetics.

[43]  Guillermo Repetto,et al.  Neutral red uptake assay for the estimation of cell viability/cytotoxicity , 2008, Nature Protocols.

[44]  Ivan Dikic,et al.  Atypical ubiquitin chains: new molecular signals , 2008, EMBO reports.

[45]  C. Chu,et al.  Role of autophagy in G2019S‐LRRK2‐associated neurite shortening in differentiated SH‐SY5Y cells , 2008, Journal of neurochemistry.

[46]  C. Olanow,et al.  Leucine‐rich repeat kinase 2 (LRRK2)/PARK8 possesses GTPase activity that is altered in familial Parkinson’s disease R1441C/G mutants , 2007, Journal of neurochemistry.

[47]  M. Cookson,et al.  The R1441C mutation of LRRK2 disrupts GTP hydrolysis. , 2007, Biochemical and biophysical research communications.

[48]  C. Ross,et al.  Kinase activity of mutant LRRK2 mediates neuronal toxicity , 2006, Nature Neuroscience.

[49]  David W. Miller,et al.  Kinase activity is required for the toxic effects of mutant LRRK2/dardarin , 2006, Neurobiology of Disease.

[50]  C. Ross,et al.  Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[51]  G. Schackert,et al.  Identification of Uncommon Chromosomal Aberrations in the Neuroglioma Cell Line H4 by Spectral Karyotyping , 2001, Journal of Neuro-Oncology.

[52]  J. M. Bravo-San Pedro,et al.  The LRRK2 G2019S mutant exacerbates basal autophagy through activation of the MEK/ERK pathway , 2012, Cellular and Molecular Life Sciences.

[53]  M. Netea,et al.  Genomewide association study of leprosy. , 2010, The New England journal of medicine.

[54]  R. Huebner,et al.  Propagation of human tumors in antithymocyte serum-treated mice. , 1974, Journal of the National Cancer Institute.